Diabetic dyslipidemia or ‘diabetes lipidus’?

References

• Merkler M, Reiner Ž. The burden of hyperlipidaemia and diabetes in cardiovascular diseases. Fundament. Clin. Pharmacol.21(Suppl. 2), 1–3 (2007).
   PubMed Web of Science ®Google Scholar
• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract.87, 4–14 (2010).
   PubMed Web of Science ®Google Scholar
• Roglic G, Unwin N. Mortality attributable to diabetes: estimates for the year 2010. Diabetes Res. Clin. Pract.87, 15–19 (2010).
   PubMed Web of Science ®Google Scholar
• Taskinen MR. Diabetic dyslipidaemia. Atherosclerosis (Suppl. 3), 45–51 (2002).
   Google Scholar
• Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care16, 434–444 (1993).
   PubMed Web of Science ®Google Scholar
• United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet352(9131), 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• Chalmers J, Cooper ME. UKPDS and the legacy effect. N. Engl. J. Med.359, 1618–1620 (2008).
   PubMed Web of Science ®Google Scholar
• Lopes-Virella MF, Carter RE, Gilbert GE et al. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC Cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care31, 2006–2012 (2008).
   PubMedGoogle Scholar
• Landmesser U, Harrison DG, Drexler H. Oxidant stress: a major cause of reduced endothelial nitric oxide availability in cardiovascular disease. Eur. J. Clin. Pharmacol.62(Suppl. 1), 13–19 (2006).
   Web of Science ®Google Scholar
• Bendall JK, Rinze R, Adlam D, Tatham AL, de Bono J, Channon KM. Endothelial Nox2 overexpression potentiates vascular oxidative stress and hemodynamic response to angiotensin II studies in endothelial-targeted Nox2 transgenic mice. Circ. Res.100, 1016–1025 (2007).
   PubMed Web of Science ®Google Scholar
• Abe J, Kusuhara M, Ulevitch RJ, Berk BC, Lee JD. Big mitogen-activated protein kinase 1 (BMK1) is a redox-sensitive kinase. J. Biol. Chem.271, 16586–16590 (1996).
   PubMed Web of Science ®Google Scholar
• Xinchun P, Chen Y, Berk BC. Big mitogen-activated protein kinase (BMK1)/ERK5 protects endothelial cells from apoptosis. Circ. Res.94, 362–369 (2004).
   PubMedGoogle Scholar
• Woo CH, Shishido T, McClain C et al. Extracellular signal-regulated kinase 5 SUMOylation antagonizes shear stress-induced antiinflammatory response and endothelial nitric oxide synthase expression in endothelial cells. Circ. Res.102, 538–545 (2008).
   PubMed Web of Science ®Google Scholar
• Griffin E, Re A, Hamel N et al. A link between diabetes and atherosclerosis: glucose regulates expression of CD36 at the level of translation. Nat. Med.7, 840–846 (2009).
   Google Scholar
• Fuchs FD. The ADVANCE trial. Lancet371(9606), 25 (2008).
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med.358, 2545–2559 (2008).
   PubMed Web of Science ®Google Scholar
• Drexel H, Aczel S, Marte T et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care28, 101–107 (2005).
   PubMed Web of Science ®Google Scholar
• Chapman MJ. Metabolic syndrome and Type 2 diabetes: lipid and physiological consequences. Diab. Vasc. Dis. Res.4(Suppl. 3), S5–S8 (2007).
   PubMedGoogle Scholar
• Fruchart JC, Sacks F, Hermans MP et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am. J. Cardiol.102, 1K–34K (2008).
   Web of Science ®Google Scholar
• Betteridge DJ, Morrell JM. Clinicians’ Guide to Lipids and Coronary Heart Disease. Chapman & Hall, London, UK, 16 (1998).
   Google Scholar
• Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr. Opin. Lipidol.5, 339–349 (1994).
   PubMedGoogle Scholar
• Ginsberg H, Plutzky J, Sobel BE. A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering. J. Cardiovasc. Risk6, 337–346 (1999).
   PubMedGoogle Scholar
• Durrington PN. Lipids and their metabolism. In: Hyperlipidaemia, Diagnosis and Management (2nd Edition). Butterworth-Heinemann, Oxford, UK (1995).
   Google Scholar
• Goldberg IJ. Diabetic dyslipidemia: causes and consequences. J. Clin. Endocrinol. Metab.86(3), 965–971 (2001).
   PubMed Web of Science ®Google Scholar
• Stralfors P, Honnor RC. Insulin-induced dephosphorylation of hormone-sensitive lipase. Correlation with lipolysis and cAMP-dependent protein kinase activity. Eur. J. Biochem.182, 379–385 (1989).
   PubMedGoogle Scholar
• Durrington P, Sniderman A. Secondary hyperlipidemia. In: Hyperlipidemia. Durrington P, Sniderman A (Eds). Health Press, Oxford, UK, 71–89 (2002).
   Google Scholar
• Lewis GF, Steiner G. Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state. Diabetes Care19, 390–393 (1996).
   PubMed Web of Science ®Google Scholar
• Dixon JL, Furukawa S, Ginsberg HN. Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B. J. Biol. Chem.266, 5080–5086 (1991).
   PubMedGoogle Scholar
• Taghibiglou C, Carpentier A, van Iderstine SC et al. Mechanisms of hepatic very LDL overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J. Biol. Chem.275, 8416–8425 (2000).
   PubMed Web of Science ®Google Scholar
• Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very LDL production in humans. J. Clin. Invest.95, 158–166 (1995).
   PubMed Web of Science ®Google Scholar
• Krauss RM. Lipids and lipoproteins in patients with Type 2 diabetes. Diabetes Care27(6), 1496–1504 (2004).
   PubMed Web of Science ®Google Scholar
• Lee ET, Welty TK, Fabsitz R et al. The Strong Heart Study. A study of cardiovascular disease in American Indians: design and methods. Am. J. Epidemiol.132, 1141–1155 (1990).
   PubMed Web of Science ®Google Scholar
• Gotto AM Jr, Whitney E, Stein EA et al. Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Eur. Heart J.21(19), 1627–1633 (2000).
   PubMedGoogle Scholar
• Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur. Heart J.28, 2375–2414 (2007).
   PubMed Web of Science ®Google Scholar
• Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet358(9298), 2026–2033 (2001).
   PubMed Web of Science ®Google Scholar
• Durrington P, Sniderman A. Epidemiology and pathophysiology. In: Hyperlipidemia. Durrington P, Sniderman A (Eds). Health Press, Oxford, UK, 71–89 (2002).
   Google Scholar
• Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res.96, 1221–1232 (2005).
   PubMed Web of Science ®Google Scholar
• Reiner Ž. How to improve cardiovascular diseases prevention in Europe? Nutr. Metab. Cardiovasc. Dis.19, 451–454 (2009).
   PubMedGoogle Scholar
• Verges B, Brun JM, Vaillant G et al. Influence of obesity and hypertriglyceridaemia on the low HDL2-cholesterol level and on its relationship with prevalence of atherosclerosis in Type 2 diabetes. Diabetes Metab.18(4), 289–297 (1992).
   Google Scholar
• Rashid S, Barrett PH, Uffelman KD et al. Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscler. Thromb. Vasc. Biol.22, 483–487 (2002).
   PubMed Web of Science ®Google Scholar
• Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidaemia, inflammation, and atherosclerosis. Pharmacol. Rev.58, 342–374 (2006).
   PubMed Web of Science ®Google Scholar
• Benedict C, Scheller J, Rose-John S, Born J, Marshall L. Enhancing influence of intranasal interleukin-6 on slow-wave activity and memory consolidation during sleep. FASEB J.23(10), 3629–3636 (2009).
   PubMedGoogle Scholar
• Peter CH, Castellt JV, Andust T. Interleukin-6 and the acute phase response. Biochem. J.265, 621–636 (1990).
   PubMedGoogle Scholar
• Muačević-Katanec D, Bradamante V, Poljičanin T et al. Clinical study on the effect of simvastatin on paraoxonase activity. Arzneimittelforschung57(10), 647–653 (2007).
   PubMed Web of Science ®Google Scholar
• Van Lenten BJ, Hama SY, de Beer FC et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest.96, 2758–2767 (1995).
   PubMed Web of Science ®Google Scholar
• Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol.15, 1812–1818 (1995).
   PubMed Web of Science ®Google Scholar
• La Du BN, Novais J. Human serum organophosphatase: biochemical characteristics and polymorphic inheritance. In: Enzymes Hydrolysing Organophosphorus Compounds. Reiner E, Aldridge WN, Hoskin FCG (Eds). Ellis-Horwood, Chichester, UK, 41–52 (1989).
   Google Scholar
• Lee ET, Welty TK, Fabsitz R et al. The Strong Heart Study. A study of cardiovascular disease in American Indians: design and methods. Am. J. Epidemiol.132, 1141–1155 (1990).
   PubMed Web of Science ®Google Scholar
• Betteridge DJ, Morrell JM. Diabetic patient. In: Clinicians’ Guide to Lipids and Coronary Heart Disease. Betteridge DJ, Morrell JM (Eds). Chapman & Hall, London, UK, 232–233 (1998).
   Google Scholar
• Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care24, 683–689 (2001).
   PubMed Web of Science ®Google Scholar
• Adlerberth AM, Rosengren A, Wilhelmsen L. Diabetes and long-term risk of mortality from coronary and other causes in middle-aged Swedish men. A general population study. Diabetes Care21, 539–545 (1998).
   PubMed Web of Science ®Google Scholar
• Drexel H, Aczel S, Marte T, Benzer W, Langer P, Moll W, Saely CH. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care28, 101–107 (2005).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Baro MR, Lewin TM, Coleman RA. Regulation of triglyceride metabolism. II. Function of mitochondrial GPAT1 in the regulation of triacylglycerol biosynthesis and insulin action. Am. J. Physiol. Gastrointest. Liver Physiol.292, G1195–G1199 (2007).
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch. Med. Res.36, 232–240 (2005).
   PubMed Web of Science ®Google Scholar
• Lewis GF, Steiner G. Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state. Diabetes Care19, 390–393 (1996).
   PubMed Web of Science ®Google Scholar
• Cornier MA, Dabelea D, Hernandez TL. The metabolic syndrome. Endocr. Rev.29, 777–822 (2008).
   PubMed Web of Science ®Google Scholar
• McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of Type 2 diabetes. Diabetes51, 7–18 (2002).
   PubMed Web of Science ®Google Scholar
• Pan DA, Lillioja S, Kriketos AD et al. Skeletal muscle triglyceride levels are inversely related to insulin action Diabetes46, 983–988 (1997).
   PubMed Web of Science ®Google Scholar
• Poitout V, Robertson RP. Minireview: Secondary β-cell failure in Type 2 diabetes – a convergence of glucotoxicity and lipotoxicity. Endocrinology143(2), 339–342 (2002).
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet364(9435), 685–696 (2004).
   PubMed Web of Science ®Google Scholar
• Knopp RH, d’Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with Type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease End points in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care29(7), 1478–1485 (2006).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Nutrition principles and recommendations in diabetes (Position Statement). Diabetes Care27(Suppl. 1), S36–S46 (2004).
   PubMedGoogle Scholar
• American Diabetes Association. Physical activity/exercise and diabetes (position statement). Diabetes Care27, S58–S62 (2004).
   PubMed Web of Science ®Google Scholar
• Reiner Ž. Combined therapy in the treatment of dyslipidemia. Fundam. Clin. Pharmacol.24, 19–28 (2010).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care27(Suppl. 1), S68–S71 (2004).
   PubMedGoogle Scholar